Key result
Among patients receiving 4-Factor PCC for life-threatening bleeding, 16.5% developed thromboembolic complications within 14 days, with higher risk in those receiving >1 dose.
Why the study?
Little is known about the risk of developing thromboembolic complications in previously anticoagulated patients receiving prothrombin complex concentrate for life-threatening bleeding.
What is the rate of thromboembolic complications in adult patients receiving 4-Factor PCC for life-threatening bleeding associated with oral anticoagulants?
Observational (n=333)
What is the rate of thromboembolic complications in adult patients receiving 4-Factor PCC for life-threatening bleeding associated with oral anticoagulants?
Answers are grounded in this paper and cite their sources.
Administration of 4-Factor PCC for life-threatening bleeding carries a 16.5% risk of thromboembolic complications within 14 days, with increased risk in patients receiving multiple doses, those on rivaroxaban, and those with a prior history of thromboembolism.
Purpose: Patients presenting with life-threatening bleeding associated with oral anticoagulants (OACs) are challenging with few available treatments. Prothrombin complex concentrate (PCC) is an option for OAC reversal in the setting of life-threatening bleeding with a relatively benign safety profile. Little is known about the risk of developing thromboembolic complications (TEC) in patients receiving PCC who were previously anticoagulated. The aim of this study is to characterize the rate of TEC after receipt of PCC. Methods: All adult patients who received 4-Factor PCC for life-threatening bleeding were retrospectively evaluated over a 2-year time period. Data collected included anticoagulant and indication, bleeding source, PCC dose, INR, and TEC within 14 days of PCC dose, including venous thromboembolism (VTE), acute myocardial infarction, and ischemic stroke. Results: Three hundred thirty-three patients received 383 PCC doses. Of these, 55 (16.5%) patients developed TEC, including VTE, ischemic stroke, and acute myocardial infarction. There was increased rivaroxaban use in patients who developed TEC (25.4% vs 12.2%; P = .011). Additionally, there were more patients who had anticoagulation for a previous TEC in those who developed a new TEC (38.2% vs 23.4%; P = .022). Lastly, there was a higher rate of TEC in those who received >1 dose of PCC (21.8% vs 7.9%; P = .002). Conclusion: PCC administration in the setting of life-threatening bleeding is not benign. Risk of TEC increases in patients who have rivaroxaban reversal, receive a repeat dose of PCC, and have a TEC indication for their anticoagulation and these factors should be further investigated.
No takes yet. Share an insight, caveat, or question.
Owen et al. (2020) conducted an observational in Life-threatening bleeding associated with oral anticoagulants (n=333). 4-Factor Prothrombin complex concentrate (PCC) was evaluated on Thromboembolic complications (TEC) within 14 days. Among patients receiving 4-Factor PCC for life-threatening bleeding, 16.5% developed thromboembolic complications within 14 days, with higher risk in those receiving >1 dose.
Synapse has enriched 10 related papers. Consider them for comparative context: